YMEA Ménopause Tonus et Vitalité
Food supplement declared in France, declaration No 2017-3-710
YMEA Ménopause Tonus et Vitalité, from LABORATOIRE PERRIGO FRANCE, is a food supplement declared in France. Status: withdrawn from the market on 30 June 2020. Main ingredients: Actaea racemosa 100 mg per day, Vitex agnus-castus 24 mg per day, Pantothenic acid (vitamin B5), Folate (vitamin B9), Vitamin B12. 1 point in its composition requires a check (prohibited substance, dose or novel food). 2 rules of use apply to its ingredients (limits and warnings).
- Brand
- YMEA
- Food business operator placing the product on the market
- LABORATOIRE PERRIGO FRANCE
- Status
- Withdrawn from the market on 30 June 2020
- Form
- Tablet
- Daily dose
- 1 comprimé
- Directions for use
- Prendre 1 comprimé avec un grand verre d'eau au cours du petit-déjeuner
- Intended populations
- Women
- Not recommended (according to the manufacturer)
- Breastfeeding women, History of breast cancer, Pregnant women, Liver problems
- Objectives stated by the manufacturer (these are not authorised claims)
- Menopause
- Flavourings
- aucun
Declaration 161570, procedure Article 16. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.
Declared composition
Plants
| Plant | Part | Preparation | Per day |
|---|---|---|---|
| Actaea racemosa L. | Racine | Extrait sec aqueux | 100 mg |
| Vitex agnus-castus L. | Fruit | Extrait sec hydroalcoolique | 24 mg |
Vitamins and minerals
Compl'Alim does not publish vitamin and mineral doses. The references below help you read the product label: EFSAEuropean Food Safety Authority. safety limit for adults and maximum dose set in France per product (Order of 9 May 2006, not revised since November 2006).
| Declared form | Nutrient | EFSA limit, adults | Maximum dose in France |
|---|---|---|---|
| D-pantothenate, calcium | Pantothenic acid (vitamin B5) | no limit (insufficient data) | dose annulled by the French Council of State in 2011 |
| pteroylmonoglutamic acid | Folate (vitamin B9) | 1,000 µg | 200 µg |
| cyanocobalamin | Vitamin B12 | no adverse effect defined | dose annulled by the French Council of State in 2011 |
| pyridoxine hydrochloride | Vitamin B6 | 12 mg | 2 mg |
| L-ascorbic acid | Vitamin C | no limit (insufficient data) | 180 mg |
| cholecalciferol | Vitamin D | 100 µg (4,000 IU) | 5 µg (200 IU) |
| zinc oxide | Zinc | 25 mg | 15 mg |
Additives
E460, E463, E464, E570, E553b, E171, E172, E551, E470b, E421
Other ingredients
maltodextrine
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.
Label warnings
- Réservé à l'adulte.
Regulatory points
- À vérifier
The composition lists additive E171 (titanium dioxide), removed from the list of additives allowed in food, supplements included: since 7 August 2022, a supplement containing it can no longer be placed on the market in the Union.
Source: Regulation (EU) 2022/63: titanium dioxide (E171) removed from the food additives allowed in the EU, règlement (UE) 2022/63.
- Conditions légales
Actaea racemosa L.: Seuls les extraits aqueux et hydro-alcooliques de titre faible (30 %) sont admis. La portion journalière recommandée ne doit pas conduire à une ingestion de glycosides de triterpène (calculés comme 27-déoxyactéine) supérieure à 3 mg.
Source: French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, arrêté du 24 juin 2014, annexe I.
- Conditions légales
Vitex agnus-castus L.: L'étiquetage doit comporter un avertissement déconseillant l'usage chez les femmes ayant des antécédents personnels ou familiaux de cancer du sein.
Source: French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, arrêté du 24 juin 2014, annexe I.
- Information
Withdrawn from the market on 30 June 2020, according to Compl'Alim.
Source: Compl'Alim, food supplement declarations (France).
This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Actaea racemosa L.
Read the warning, when it applies and the studies cited
Black Cohosh - Actaea Racemosa
Route of administration: Oral
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are breastfeeding.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a liver disorder or develop symptoms of liver trouble (EMA 2018, 2007; Lynch et al. 2006; Mills et al. 2006; Cohen et al. 2004; NIH 2004).
Sources cited by Health Canada (6)
- Cohen SM, O'Connor AM, Hart J, Merel NH, Te HS. Autoimmune hepatitis associated with the use of black cohosh: a case study. Menopause: the Journal of the North American Menopause Society 2004;11(5):575-577. PubMed Case report
- EMA 2018: European Medicines Agency. Committee on Herbal Medicinal Products (HMPC). European Union Herbal monograph on Cimicifuga racemosa (L.) Nutt., rhizome. March 2018. [Accessed 2025 January 3]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-cimicifuga-racemosa-l-nutt-rhizome-revision-1_en.pdf
- EMA 2007: European Medicines Agency. Committee on Herbal Medicinal Products (HMPC) Annex 1. Assessment of case reports connected to herbal medicinal products containing Cimicifugae racemosae rhizoma (Black cohosh, root). London (UK): European Medicines Agency; May 20027. [Accessed 2025 January 3]. Available from: https://www.ema.europa.eu/en/documents/herbal-report/assessment-case-reports-connected-herbal-medicinal-products-containing-cimicifugae-racemosae-rhizoma-black-cohosh-root_en.pdf
- Lynch CR, Folkers ME, Hutson WR. Fulminant hepatic failure associated with the use of black cohosh: a case report. Liver Transplantation 2006;12(6):989-992. PubMed Case report
- Mills E, Duguoa J, Perri D, Koren G. Herbal Medicines in Pregnancy and Lactation. New York (NY): Taylor and Francis; 2006.
- NIH 2004: National Institutes of Health. Workshop on the Safety of Black Cohosh in Clinical Studies. Bethesda (MD): National Institutes of Health, Department of Health and Human Services; November 22, 2004. [Accessed 2024 December 3]. Available from: https://files.nccih.nih.gov/s3fs-public/news/blackcohosh_mtngsumm.pdf
Contraindications
Do not use if you are pregnant (Brinker 2010; Hoffmann 2003; Tilgner 1999).
Sources cited by Health Canada (3)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Hoffmann D. Medical Herbalism. Rochester (VT): Healing Arts Press; 2003.
- Tilgner S. Herbal Medicine from the Heart of the Earth Creswell (OR): Wise Acre Press; 1999.
- Vitex agnus-castus L.
Read the warning, when it applies and the studies cited
CHASTE TREE - VITEX AGNUS-CASTUS
Route of administration: Oral (WHO 2009; Bradley 2006; Mills and Bone 2000)
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking hormone-containing medications such as progesterone preparations, oral contraceptives or hormone replacement therapy (Brinker 2010; WHO 2009; Bradley 2006).
Sources cited by Health Canada (4)
- Bradley PR, editor. 2006. British Herbal Compendium: A Handbook of Scientific Information on Widely Used Plant Drugs, Volume 2. Bournemouth (GB): British Herbal Medicine Association.
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- WHO 2009: World Health Organization. WHO Monographs on Selected Medicinal Plants, Volume 4. Geneva (CH): World Health Organization.
- OMS 2009: Organisation mondiale de la santé. WHO Monographs on Selected Medicinal Plants, Volume 4. Genève (CH): Organisation mondiale de la santé.
Contraindications
Do not use if you are pregnant, breastfeeding or attempting to conceive unless you have consulted with a health care practitioner/health care provider/health care professional/doctor/physician (EMA 2018; Najib et al. 2022; Brinker 2010; WHO 2009; Dugoua et al. 2008; ESCOP 2003; Blumenthal 2000; Mills and Bone 2000).
Sources cited by Health Canada (9)
- Blumenthal M, Goldberg A, Brinkmann J, editors. 2000. Herbal Medicine: Expanded Commission E Monographs. Boston (MA): Integrative Medicine Communications.
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Dugoua JJ, Seely D, Pern D, Koren G, Mills E. Safety and efficacy of chastetree (Vitex Agnus-Castus) during pregnancy and lactation. Can J. Clin Pharmacol 2008;15(1);e74-e79.
- EMA 2018. European Medicines Agency. European Union herbal monograph on Vitex agnus-castus L., fructus. London (GB): EMA Committee on Herbal Medicinal Products (HMPC); 27 March 2018. [Accessed 2024 February 29] Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-vitex-agnus-castus-l-fructus-revision-1_en.pdf
- ESCOP 2003: European Scientific Cooperative on Phytotherapy Scientific Committee. ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy in collaboration with Thieme.
- Mills S, Bone K. 2000. Principles and Practice of Phytotherapy. Toronto (ON): Churchill Livingstone.
- Najib FS, Poordast T, Mahmudi MS, Shiravani Z, Namazi N, Omrani GR. Does Vitex Agnus-Castus L. Have Deleterious Effect on Fertility and Pregnancy Outcome? An Experimental Study on Rats for Prediction of Its Safety. J. Pharmacopuncture 2022;25(2):106-113. PubMed
- WHO 2009: World Health Organization. WHO Monographs on Selected Medicinal Plants, Volume 4. Geneva (CH): World Health Organization.
- OMS 2009: Organisation mondiale de la santé. WHO Monographs on Selected Medicinal Plants, Volume 4. Genève (CH): Organisation mondiale de la santé.
They concern the ingredient, not this product or its dose. They do not replace medical advice.
Brand : YMEA
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.
Cite this page: CompoAtlas, “YMEA Ménopause Tonus et Vitalité: composition and regulation”, https://compoatlas.com/en/supplements/products/161570-ymea-menopause-tonus-et-vitalite, updated 15 November 2026.